AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04376489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages (participants experiencing negative affect & cigarettes are not available)
Description: Participants receive messages tailored for situations when they experiencing negative affect.
Study NCT04376489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages (participants not experiencing negative affect & cigarettes are not available)
Description: Generic messages for situations when participants are neither experiencing negative affect nor cigarettes are available.
Study NCT04376489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moodsurf
Description: Smart phone app that teaches participants a mindfulness-based technique in which participant surf the mood.
Study NCT04376489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditate
Description: Smart phone app that teaches participants a mindfulness-based meditation designed for smoking cessation.
Study NCT04376489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joy
Description: Smart phone app that teaches participants to practice breathing exercise.
Study NCT04376489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagine
Description: Smart phone app that teaches participants to use their imagination to explore and manage their thoughts and feelings.
Study NCT04376489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Notice
Description: Smart phone app that teaches participants to accept their thoughts and feelings.
Study NCT03951428 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Menstrual Blood Screening Test
Description: The sponsor will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing three early stage cancers via self-collected menstrual blood using FDA approved devices.
Study NCT04328948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Chemoradiotherapy
Study NCT04328948 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Chemoradiotherapy
Study NCT03522779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry Juice
Description: Tart cherry juice will be used to compare antioxidant and oxidative stress levels in human plasma following a high fat meal.
Study NCT03522779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High-fat meal
Description: A high fat meal will be given to elicit postprandial oxidative stress.
Study NCT03522779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal
Description: A high fat meal will be given to elicit postprandial oxidative stress.
Study NCT03522779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
Study NCT00996125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CervarixTM
Description: Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
Study NCT00996125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
Study NCT03595514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single injection
Description: Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
Study NCT03595514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double injection
Description: Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
Study NCT03595514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine, bupivacaine, epinephrine, dexamethasone
Description: lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
Study NCT03595514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine, bupivacaine, epinephrine, dexamethasone
Description: lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
Study NCT03938844 — intervention group
Intervention type: PROCEDURE
Intervention: BURCH Colposuspension
Description: stress urinary incontinence surgery ( burch or tot)
Study NCT03938844 — intervention group
Intervention type: PROCEDURE
Intervention: TOT
Study NCT03806855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: 3-day bladder diary
Study NCT00980239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Starting dose of 35 mg/m\^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).
Study NCT00980239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.
Study NCT00980239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose 60 mg/m\^2 by vein over 2 hours on Days 1 and 15 of every cycle.
Study NCT00980239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m\^2 by vein on Days 1 and 15 of every cycle. The first time given over 2 hours, all other cycles over 1 hour.
Study NCT00026494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00026494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study NCT00665431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN 400 (VIMOVO)
Description: 500 mg naproxen/20 mg esomeprazole bid
Study NCT00665431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celebrex
Description: 200 mg celecoxib qd
Study NCT00665431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill bid
Study NCT00665431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Antacid
Description: Antacid Tablets
Study NCT00665431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Antacid
Description: Antacid Tablets
Study NCT00665431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Antacid
Description: Antacid Tablets
Study NCT04815811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.
Study NCT04815811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.
Study NCT04815811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool collection
Description: Fecal sample collection to delineate microbiome contribution, we will study the gut microbiota in faecal samples obtained from the recruited patients.
Study NCT02134015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab
Description: Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
Study NCT02134015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Oral erlotinib 150 mg/day
Study NCT02134015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo infusion every 3 weeks
Study NCT00979316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
Study NCT00979316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
Study NCT00979316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
Study NCT00979316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
Study NCT01732458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.
Study NCT01732458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Aprepitant
Study NCT01732458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Administered IV at a dose of 4 mg for participants >40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants \<1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.
Study NCT01732458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ondansetron
Description: Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
Study NCT03962777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: patients used chx moutrinses for four days
Study NCT03962777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oil pulling
Description: patients used oil pulling for four days
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10mg
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Telmisartan 80mg)
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(for Telmisartan 80mg)
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(for Rosuvastatin 20mg)
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Rosuvastatin 20mg)
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(for Rosuvastatin 20mg)
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(for Rosuvastatin 10mg)
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Rosuvastatin 10mg)
Study NCT02087540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(for Rosuvastatin 10mg)
Study NCT01154114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib
Description: darapladib 40 mg oral dose
Study NCT03805035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture
Description: Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
Study NCT03805035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
Study NCT03805035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate)
Description: Group 3 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 1 tab);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
Study NCT03805035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antihistamine(high dose) chlorpheniramine (Dexchlorpheniramine maleate)
Description: Group 4 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate2mg/tab, 2 tabs);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
Study NCT03805035 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Minimal needling at ST36 and GB34
Study NCT03494634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
Study NCT02484274 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: 1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
Study NCT04080388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung Impedance Device
Description: The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.
Study NCT04080388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-congestive treatment
Description: Continuation of in-hospital anti-congestive treatment
Study NCT01736345 — intervention group
Intervention type: GENETIC
Intervention: Genetic Providers
Description: Genetic providers (genetic counselors or nurses) will follow the standardized disclosure protocol for in-person and telephone disclosures whle completing a disclosure flow checklist.
Study NCT01736345 — intervention group
Intervention type: OTHER
Intervention: Visual Aids
Description: Visual aids targeted to facilitate communication of genetic test results were developed based on our preliminary studies and modified based on our initial pilot study.
Study NCT01736345 — intervention group
Intervention type: OTHER
Intervention: Post-Disclosure Asessments
Description: Within 72 hours of completion of disclosures, participants will be asked to complete post-disclosure survey again being the option to complete by the aforementioned means.
Study NCT01736345 — intervention group
Intervention type: OTHER
Intervention: In-person Clinical Follow-Up
Description: Participants who receive their test results in person will meet with a Physician, Physician Assistant or Nurse Practitioneras part of their in person disclosure session. Participants randomiZed to telephone disclosure will be recommendedto schedule an in-person clinical follow-up appointment with a Physician, Physician Assistant or Nurse Practitioner
Study NCT01736345 — intervention group
Intervention type: OTHER
Intervention: 6 Month and 12 Month Assessments
Description: At 6 months and 12 months after disclosure participants will be asked to complete survey assessments.
Study NCT03230058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
Description: instillation of drops
Study NCT03230058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
Description: instillation of drops
Study NCT04338841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOME-CoV rule implementation
Description: HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.~Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments.
Study NCT01500382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
Study NCT01500382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine ER
Description: Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
Study NCT03749616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
Study NCT01500382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
Study NCT01500382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (vibegron)
Description: Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
Study NCT03749616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
Study NCT02711553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02711553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally
Study NCT02711553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV
Study NCT02711553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Administered IV
Study NCT02711553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT02711553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV
Study NCT02711553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: Administered orally
Study NCT02711553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Administered IV
Study NCT01500382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (vibegron)
Description: Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
Study NCT01500382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (tolterodine ER)
Description: Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
Study NCT01500382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (tolterodine ER)
Description: Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
Study NCT01500382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Antibiotic
Description: A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
Study NCT01500382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Antibiotic
Description: A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
Study NCT01600027 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fascia iliaca compartment block
Description: Fascia iliaca compartment block was performed as described by Dalens et al technique.
Study NCT01600027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca block
Description: Fascia iliaca compartment block was performed as described by Dalens et al technique.
Study NCT03306628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 Laser Administration
Description: The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).
Study NCT02768727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: drug given in concentrations of 0% to 60% over period of 2 hours
Study NCT01866111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP3089
Study NCT01866111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo